Analyzing eye fluid biomarkers in patients with retinal diseases
Official title: Analysis of Biomarkers From Patients With Chorioretinal Diseases
Run by Kyungpook National University Hospital · NCT02026843 · Data updated 2026-11-12
This study is trying to see if certain eye fluids can help us understand how serious retinal diseases like diabetic retinopathy and age-related macular degeneration are in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Kyungpook National University Hospital Academic / other |
| Locations | 1 site (Daegu, Kyungsangpookdo) |
| Status | Recruiting |
| Started | April 2012 |
| Main results expected | February 2028 |
| Study ends | April 2031 |
| Registry record updated | March 6, 2025 |
| Trial ID | NCT02026843 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 20 years with chorioretinal diseases or those requiring cataract surgery.
✕Probably not a fit
Patients under 20 years or those with recent ocular trauma or infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates ocular biomarkers in patients suffering from chorioretinal diseases such as diabetic retinopathy and age-related macular degeneration. It includes a total of 100 participants, with 50 patients diagnosed with chorioretinal diseases and 50 control patients undergoing cataract surgery or vitrectomy. Ocular fluids and blood samples are collected prior to treatment to analyze the levels of specific biomarkers. The goal is to better understand the relationship between these biomarkers and the severity of retinal diseases.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients with chorioretinal diseases.
How similar studies have gone: Other studies have shown promise in analyzing ocular biomarkers for retinal diseases, suggesting this approach has potential.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age over 20 years * patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity. * patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. * control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders. Exclusion Criteria: * under the age of 20 years * patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor * patients that did not signed the informed consent of the trial * patients with intraocular inflammations or infections that requiring any pharmaceutical agent * patients with recent ocular trauma
Where it's running
-
Dong Ho Park
Daegu, Kyungsangpookdo, South Korea Recruiting
Study contacts
- Principal investigator: Dong Ho Park, M.D — Kyungpook National University Hospital
- Study coordinator: Dong Ho Park, M.D.
- Email: sarasate2222@gmail.com
- Phone: 82-53-420-5813
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exploring new imaging techniques for eye diseases
This study is testing a new eye imaging technique to better understand diseases like diabetic retinopathy and macular degeneration in order to improve treatment for patients.
-
Using stem cells from umbilical cords to treat non-arteritic ischemic optic neuropathy
This study is testing if using stem cells from umbilical cords can help people with non-arteritic ischemic optic neuropathy improve their vision and overall eye health.
-
MB-102 versus fluorescein sodium for retinal angiography imaging
This trial will test whether the new dye MB-102 produces safe, high-quality retinal angiography images in adults with healthy eyes or retinal vascular disease compared with standard fluorescein sodium.
-
Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy
This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.
-
Noninvasive imaging biomarkers to see if ophthalmic artery narrowing relates to geographic atrophy in age-related macular degeneration
This study tests whether narrowed ophthalmic artery vessels are linked to the development or worsening of geographic atrophy in people with dry age-related macular degeneration.
-
Automated detection of diabetic retinopathy lesions in fundus photos
This study tests a smart imaging system within the DDART device to see if it can reliably spot diabetic retinopathy lesions in color fundus photographs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.